10x Genomics
TXG Healthcare Medical Devices
10x Genomics' revenue for fiscal 2025 (year ended December 2025) was $642.8 million, up 5.25% from fiscal 2024.
- Revenue
- +1.12%
- EPS
- +31.8%
- Free cash flow
- −4.61%
Quarter to September 2026, against a year earlier
Follow TXG
Alert me
10x Genomics (TXG) EV/FCF
As of 5 November 2026, 10x Genomics (TXG) trades at a EV/FCF of 76.8×. Over the past ten years it has ranged from −1,213× (January 2020) to 132× (October 2026); the current reading is higher than 98% of that period.
EV/FCF, daily
Embed this chart
Annual newest first
| Period | EV/FCF | Change |
|---|---|---|
| FY2025 | 11.9× | — |
| FY2024 | −203× | — |
| FY2023 | −92.8× | — |
| FY2022 | −21.9× | — |
| FY2021 | −129× | — |
| FY2020 | −53.7× | — |
| FY2019 | −854× | — |
| FY2018 | −7.4× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | EV/FCF | Change |
|---|---|---|
| Sep 2026 | 122× | 228.06% |
| Jun 2026 | 37.0× | 102.79% |
| Mar 2026 | 18.3× | 53.05% |
| Dec 2025 | 11.9× | (5.14%) |
| 27 more quarters | Free account |
Against its own ten years
EV/FCF against peers
| Company | EV/FCF |
|---|---|
| SNN Smith & Nephew SNATS, Inc. compare | 8.3× |
| GMED Globus Medical, Inc. compare | 14.9× |
| HAE Haemonetics Corporation compare | 20.9× |
| BIO Bio-Rad Laboratories, Inc. compare | 28.8× |
| BIO.B Bio-Rad Laboratories, Inc. compare | 29.5× |
| BRKR Bruker Corporation compare | 38.8× |
| PODD Insulet Corporation compare | 48.0× |
| TXG 10x Genomics | 58.9× |
| PEN Penumbra, Inc. compare | 59.8× |
What EV/FCF is
EV/Free CF shows how the value of a whole company, debt included, compares with the free cash its business produces.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ (Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM))
More on TXG
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement